RELATIONSHIP BETWEEN DOSE, ANTI-FACTOR XA ACTIVITY, AND OUTCOMES IN PATIENTS RANDOMIZED TO EDOXABAN IN THE ENGAGE AF-TIMI 48 TRIAL

High (HD) and low doses (LD) of the FXa inhibitor edoxaban (edox) were noninferior to warfarin in preventing stroke/systemic embolism (stroke/SEE) with less bleeding in the ENGAGE-AF trial of 21,105 pts with AF. Dose was reduced 50% for impaired drug clearance. We correlated edox dose, drug levels